Study evaluating intranasal anti-CD3 for treatment of Alzheimer’s disease published in the PNAS journal

Tiziana Life Sciences Ltd. (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced acceptance of a publication, “Nasal Administration of anti-CD3 monoclonal antibody (mAb) ameliorates disease in a mouse model of Alzheimer’s disease”, in the preeminent journal, Proceedings of the National Academy of Sciences (PNAS), that supports foralumab’s mechanism as a potential treatment for Alzheimer’s disease (AD), a difficult-to-treat neuroinflammatory disease.

Kite, Epic Bio partner to develop new cancer cell therapies

Epic Bio will focus on developing constructs for targets selected by Kite for use in CAR T-cell therapies directed to blood cancers. Credit: Vladimir Zotov

November 1, 2023

New Name for Familiar Phenomenon: ‘Administrative Harm’

Clinicians have long understood that administrative decisions can cause harm, both to themselves and to their patients. Now, a term for the phenomenon is gaining

July 11, 2024

Psilocybin vs Lexapro; FDA’s KarXT Decision Nears; Obesity and Schizophrenia

In a phase II trial of moderate-to-severe major depressive disorder, 6 weeks of intensive treatment with psilocybin or escitalopram (Lexapro) plus psychological support were tied

September 26, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.